Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...

The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.

Viking Therapeutics (NASDAQ:VKTX) fell ~43% as analysts reacted to mid-stage trial data for its oral GLP-1/GIP dual receptor ...

VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in terms of body weight loss.

Viking Therapeutics Inc. plunged in early trading on Tuesday after its experimental obesity pill disappointed in a mid-stage ...

Viking Therapeutics said Tuesday its experimental weight-loss pill helped patients lose 12.2% of their body weight in a ...

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...

A doctor has explained how the body adjusts to the weight-loss drug Mounjaro during its first month of use. Weight loss drugs ...

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side ...